Cargando…
The Feasibility and Safety of Induction Chemotherapy Followed by Definitive Chemoradiation in Patients with Locally Advanced Cervical Cancer: A Single-Arm Phase II Clinical Trial
BACKGROUND: The present study aimed at investigating the feasibility and safety of induction chemotherapy followed by definitive chemoradiation (dCRT) in patients with locally advanced cervical cancer. MATERIALS AND METHODS: In this single-arm clinical trial, patients with cervical cancer (stages IB...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352727/ https://www.ncbi.nlm.nih.gov/pubmed/37116155 http://dx.doi.org/10.31557/APJCP.2023.24.4.1321 |
_version_ | 1785074571011948544 |
---|---|
author | Ahmadloo, Niloofar Heidarpourfard, Marzieh Najib, Fatemeh Sadat Shiravani, Zahra Omidvari, Shapour Mosalaei, Ahmad Mohammadianpanah, Mohammad Ansari, Mansour Nasrolahi, Hamid Khanjani, Nezhat Kadkhodaei, Behnam Hamedi, Seyed Hassan |
author_facet | Ahmadloo, Niloofar Heidarpourfard, Marzieh Najib, Fatemeh Sadat Shiravani, Zahra Omidvari, Shapour Mosalaei, Ahmad Mohammadianpanah, Mohammad Ansari, Mansour Nasrolahi, Hamid Khanjani, Nezhat Kadkhodaei, Behnam Hamedi, Seyed Hassan |
author_sort | Ahmadloo, Niloofar |
collection | PubMed |
description | BACKGROUND: The present study aimed at investigating the feasibility and safety of induction chemotherapy followed by definitive chemoradiation (dCRT) in patients with locally advanced cervical cancer. MATERIALS AND METHODS: In this single-arm clinical trial, patients with cervical cancer (stages IB3-IVA) received a median four cycles of induction chemotherapy (paclitaxel and carboplatin, every three weeks) followed by dCRT (which consisted of the whole pelvis at the dose of 45-50 Gy along with weekly cisplatin (40 mg/m(2)) followed by intracavitary brachytherapy at the total dose of 80-90 Gy). Primary end point was local control at three months, which was assessed by gynecologic examination and pelvic MRI. The secondary outcome of the study was treatment-related toxicity. RESULTS: Seventy-four patients with the mean age of 51.6 ± 9.5 years were included. The most frequent (51.4%) disease stage was IIB. Complete and partial clinical responses were observed in 60.8% and 14.9% of patients, respectively. The frequency of progressive disease and stable disease were 14.9% and 9.5%, respectively. Grade II and III neutropenia (during neoadjuvant chemotherapy were 13.5% and 2.7%, respectively; these figures during chemoradiation were 29.7% and 13.5%, respectively. A treatment interruption was observed for 60.8% (45 cases) of patients during chemoradiation and 31.1% during induction chemotherapy. DISCUSSION AND CONCLUSION: Induction chemotherapy followed by chemoradiation is feasible in patients with locally advanced cervical cancer; however, the toxicity should be managed properly to avoid delayed e treatment. More than three quarters of the patients achieved complete or partial clinical response within a three-month follow-up. |
format | Online Article Text |
id | pubmed-10352727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-103527272023-07-19 The Feasibility and Safety of Induction Chemotherapy Followed by Definitive Chemoradiation in Patients with Locally Advanced Cervical Cancer: A Single-Arm Phase II Clinical Trial Ahmadloo, Niloofar Heidarpourfard, Marzieh Najib, Fatemeh Sadat Shiravani, Zahra Omidvari, Shapour Mosalaei, Ahmad Mohammadianpanah, Mohammad Ansari, Mansour Nasrolahi, Hamid Khanjani, Nezhat Kadkhodaei, Behnam Hamedi, Seyed Hassan Asian Pac J Cancer Prev Research Article BACKGROUND: The present study aimed at investigating the feasibility and safety of induction chemotherapy followed by definitive chemoradiation (dCRT) in patients with locally advanced cervical cancer. MATERIALS AND METHODS: In this single-arm clinical trial, patients with cervical cancer (stages IB3-IVA) received a median four cycles of induction chemotherapy (paclitaxel and carboplatin, every three weeks) followed by dCRT (which consisted of the whole pelvis at the dose of 45-50 Gy along with weekly cisplatin (40 mg/m(2)) followed by intracavitary brachytherapy at the total dose of 80-90 Gy). Primary end point was local control at three months, which was assessed by gynecologic examination and pelvic MRI. The secondary outcome of the study was treatment-related toxicity. RESULTS: Seventy-four patients with the mean age of 51.6 ± 9.5 years were included. The most frequent (51.4%) disease stage was IIB. Complete and partial clinical responses were observed in 60.8% and 14.9% of patients, respectively. The frequency of progressive disease and stable disease were 14.9% and 9.5%, respectively. Grade II and III neutropenia (during neoadjuvant chemotherapy were 13.5% and 2.7%, respectively; these figures during chemoradiation were 29.7% and 13.5%, respectively. A treatment interruption was observed for 60.8% (45 cases) of patients during chemoradiation and 31.1% during induction chemotherapy. DISCUSSION AND CONCLUSION: Induction chemotherapy followed by chemoradiation is feasible in patients with locally advanced cervical cancer; however, the toxicity should be managed properly to avoid delayed e treatment. More than three quarters of the patients achieved complete or partial clinical response within a three-month follow-up. West Asia Organization for Cancer Prevention 2023 /pmc/articles/PMC10352727/ /pubmed/37116155 http://dx.doi.org/10.31557/APJCP.2023.24.4.1321 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | Research Article Ahmadloo, Niloofar Heidarpourfard, Marzieh Najib, Fatemeh Sadat Shiravani, Zahra Omidvari, Shapour Mosalaei, Ahmad Mohammadianpanah, Mohammad Ansari, Mansour Nasrolahi, Hamid Khanjani, Nezhat Kadkhodaei, Behnam Hamedi, Seyed Hassan The Feasibility and Safety of Induction Chemotherapy Followed by Definitive Chemoradiation in Patients with Locally Advanced Cervical Cancer: A Single-Arm Phase II Clinical Trial |
title | The Feasibility and Safety of Induction Chemotherapy Followed by Definitive Chemoradiation in Patients with Locally Advanced Cervical Cancer: A Single-Arm Phase II Clinical Trial |
title_full | The Feasibility and Safety of Induction Chemotherapy Followed by Definitive Chemoradiation in Patients with Locally Advanced Cervical Cancer: A Single-Arm Phase II Clinical Trial |
title_fullStr | The Feasibility and Safety of Induction Chemotherapy Followed by Definitive Chemoradiation in Patients with Locally Advanced Cervical Cancer: A Single-Arm Phase II Clinical Trial |
title_full_unstemmed | The Feasibility and Safety of Induction Chemotherapy Followed by Definitive Chemoradiation in Patients with Locally Advanced Cervical Cancer: A Single-Arm Phase II Clinical Trial |
title_short | The Feasibility and Safety of Induction Chemotherapy Followed by Definitive Chemoradiation in Patients with Locally Advanced Cervical Cancer: A Single-Arm Phase II Clinical Trial |
title_sort | feasibility and safety of induction chemotherapy followed by definitive chemoradiation in patients with locally advanced cervical cancer: a single-arm phase ii clinical trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352727/ https://www.ncbi.nlm.nih.gov/pubmed/37116155 http://dx.doi.org/10.31557/APJCP.2023.24.4.1321 |
work_keys_str_mv | AT ahmadlooniloofar thefeasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT heidarpourfardmarzieh thefeasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT najibfatemehsadat thefeasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT shiravanizahra thefeasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT omidvarishapour thefeasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT mosalaeiahmad thefeasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT mohammadianpanahmohammad thefeasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT ansarimansour thefeasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT nasrolahihamid thefeasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT khanjaninezhat thefeasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT kadkhodaeibehnam thefeasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT hamediseyedhassan thefeasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT ahmadlooniloofar feasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT heidarpourfardmarzieh feasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT najibfatemehsadat feasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT shiravanizahra feasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT omidvarishapour feasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT mosalaeiahmad feasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT mohammadianpanahmohammad feasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT ansarimansour feasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT nasrolahihamid feasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT khanjaninezhat feasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT kadkhodaeibehnam feasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial AT hamediseyedhassan feasibilityandsafetyofinductionchemotherapyfollowedbydefinitivechemoradiationinpatientswithlocallyadvancedcervicalcancerasinglearmphaseiiclinicaltrial |